Financial Snapshot

Revenue
$476.0K
TTM
Gross Margin
Net Earnings
-$33.95M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
580.8%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$63.54M
Q3 2024
Cash
Q3 2024
P/E
-1.186
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $400.0K $477.0K $14.76M $20.99M $0.00 $3.595M $4.582M $674.0K $0.00
YoY Change -16.14% -96.77% -29.71% -100.0% -21.54% 579.82%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue $400.0K $477.0K $14.76M $20.99M $0.00 $3.595M $4.582M $674.0K $0.00
Cost Of Revenue $3.348M $1.392M $0.00 $0.00
Gross Profit $11.41M $19.60M $0.00 $3.595M
Gross Profit Margin 77.31% 93.37% 100.0%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Selling, General & Admin $13.38M $16.39M $54.48M $89.54M $45.11M $14.01M $5.170M $3.750M $1.690M
YoY Change -18.38% -69.92% -39.16% 98.48% 221.94% 171.04% 37.87% 121.89%
% of Gross Profit 477.61% 456.83% 389.79%
Research & Development $16.31M $18.39M $24.96M $43.53M $51.20M $64.47M $29.01M $11.26M $2.921M
YoY Change -11.3% -26.34% -42.67% -14.98% -20.59% 122.27% 157.73% 285.31%
% of Gross Profit 218.8% 222.1% 1793.44%
Depreciation & Amortization $0.00 $100.0K $100.0K $300.0K $400.0K $300.0K $10.00K $0.00 $0.00
YoY Change -100.0% 0.0% -66.67% -25.0% 33.33% 2900.0%
% of Gross Profit 0.88% 1.53% 8.34%
Operating Expenses $16.31M $34.77M $79.44M $133.1M $76.24M $65.18M $34.18M $15.01M $4.608M
YoY Change -53.1% -56.23% -40.31% 74.54% 16.98% 90.71% 127.74% 225.65%
Operating Profit -$29.26M -$34.30M -$68.03M -$252.5M -$95.87M -$74.89M -$29.59M -$14.33M -$4.608M
YoY Change -14.69% -49.59% -73.06% 163.42% 28.02% 153.07% 106.48% 211.02%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Interest Expense $0.00 $5.600M $4.390M $921.0K $0.00 $517.0K $264.0K $0.00
YoY Change -100.0% 27.56% 376.66% -100.0% 95.83%
% of Operating Profit
Other Income/Expense, Net $1.386M $363.0K -$135.0K $1.110M -$1.440M -$941.0K $517.0K $264.0K
YoY Change 281.82% -368.89% -112.16% -177.08% 53.03% -282.01% 95.83%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Pretax Income -$27.87M -$33.93M -$73.78M -$255.8M -$95.35M -$73.95M -$29.08M -$14.07M -$4.610M
YoY Change -17.86% -54.01% -71.16% 168.29% 28.94% 154.3% 106.68% 205.21%
Income Tax $0.00 $13.00K -$448.0K -$258.0K -$176.0K $212.0K $0.00
% Of Pretax Income
Net Earnings -$28.50M -$23.20M -$73.30M -$255.6M -$95.18M -$74.16M -$29.08M -$14.07M -$4.608M
YoY Change 22.84% -68.35% -71.32% 168.52% 28.34% 155.07% 106.68% 205.3%
Net Earnings / Revenue -7125.0% -4863.73% -496.78% -1217.4% -2062.95% -634.57% -2087.24%
Basic Earnings Per Share -$2.78 -$7.28 $1.42 $7.88
Diluted Earnings Per Share -$2.78 -$7.28 $1.42 $7.88 -$12.39M -$9.493M -$5.066M -$2.568M -$841.2K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Cash & Short-Term Investments $30.62M $30.91M $42.25M $57.60M $55.90M $136.3M $59.50M $30.90M $43.80M
YoY Change -0.93% -26.84% -26.65% 3.04% -58.99% 129.08% 92.56% -29.45%
Cash & Equivalents $30.62M $30.91M $42.25M $57.60M $43.80M $49.50M $10.20M $4.000M $43.80M
Short-Term Investments $0.00 $12.10M $86.70M $49.30M $26.90M $0.00
Other Short-Term Assets $65.34M $2.194M $6.062M $6.500M $19.10M $3.300M $3.600M $600.0K $100.0K
YoY Change 2878.26% -63.81% -6.74% -65.97% 478.79% -8.33% 500.0% 500.0%
Inventory $7.291M $7.400M $1.400M
Prepaid Expenses
Receivables $173.0K $7.583M $15.80M $100.0K $0.00 $800.0K
Other Receivables $5.000M $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $95.96M $38.28M $63.19M $87.30M $76.40M $139.5M $63.90M $31.50M $43.90M
YoY Change 150.72% -39.42% -27.62% 14.27% -45.23% 118.31% 102.86% -28.25%
Property, Plant & Equipment $207.0K $0.00 $354.0K $2.100M $4.600M $100.0K $0.00 $0.00 $0.00
YoY Change -100.0% -83.14% -54.35% 4500.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $3.000M $10.40M $0.00
YoY Change -100.0% -71.15%
Other Assets $1.515M $2.483M $3.506M $4.300M $200.0K $300.0K $0.00 $100.0K $0.00
YoY Change -38.99% -29.18% -18.47% 2050.0% -33.33% -100.0%
Total Long-Term Assets $1.722M $2.483M $3.860M $6.400M $4.800M $400.0K $3.000M $10.60M $0.00
YoY Change -30.65% -35.67% -39.69% 33.33% 1100.0% -86.67% -71.7%
Total Assets $97.69M $40.76M $67.05M $93.70M $81.20M $139.9M $66.90M $42.10M $43.90M
YoY Change
Accounts Payable $1.659M $2.386M $6.510M $4.800M $19.40M $3.300M $2.500M $1.500M $600.0K
YoY Change -30.47% -63.35% 35.63% -75.26% 487.88% 32.0% 66.67% 150.0%
Accrued Expenses $4.234M $4.381M $8.942M $12.20M $4.500M $6.000M $3.400M $500.0K $100.0K
YoY Change -3.36% -51.01% -26.7% 171.11% -25.0% 76.47% 580.0% 400.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.538M $9.345M $18.41M $21.50M $29.30M $9.500M $7.800M $3.900M $800.0K
YoY Change -19.34% -49.24% -14.37% -26.62% 208.42% 21.79% 100.0% 387.5%
Long-Term Debt $0.00 $0.00 $0.00 $33.20M $32.70M $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% 1.53%
Other Long-Term Liabilities $1.412M $0.00 $1.600M $1.500M $0.00 $6.800M $8.600M $100.0K
YoY Change -100.0% 6.67% -100.0% -20.93% 8500.0%
Total Long-Term Liabilities $1.412M $0.00 $0.00 $34.80M $34.20M $0.00 $6.800M $8.600M $100.0K
YoY Change -100.0% 1.75% -100.0% -20.93% 8500.0%
Total Liabilities $8.950M $9.345M $18.41M $56.20M $63.60M $9.600M $14.60M $12.50M $800.0K
YoY Change -4.23% -49.24% -67.24% -11.64% 562.5% -34.25% 16.8% 1462.5%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015
Basic Shares Outstanding 10.27M shares 3.186M shares 51.47M shares 32.42M shares
Diluted Shares Outstanding 10.27M shares 3.186M shares 51.47M shares 32.42M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $40.271 Million

About VYNE Therapeutics Inc.

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. The firm is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Industry: Pharmaceutical Preparations Peers: Ampio Pharmaceuticals, Inc. TREX WIND-DOWN, INC. cbdMD, Inc. PLx Pharma Winddown Corp. Evofem Biosciences, Inc. Jaguar Health, Inc. JOHNSON & JOHNSON Unrivaled Brands, Inc. WEED, INC. Virpax Pharmaceuticals, Inc.